Cresset Asset Management’s AbbVie ABBV Stock Holding History

Cresset Asset Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-30,000	Closed	-$4.04M	–	1796
2023 Q2	$4.04M	Buy	+30,000	New	+$4.4M	0.01%	469

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cresset Asset Management's ABBV Position: Q1 2026 in Review

Cresset Asset Management reduced its AbbVie (ABBV) stake by 1% in Q1 2026, selling an estimated $408K and leaving 181,586 shares worth $39.5M. The position accounts for 0.17% of the portfolio, ranked #90.

Cresset Asset Management first reported a position in ABBV in Q4 2018 and has held it in 30 quarters since. The position peaked at $67.7M in Q3 2024. 4,087 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Cresset Asset Management held 181,586 shares of AbbVie worth $39.5M as of Q1 2026.
Cresset Asset Management sold 1,839 AbbVie shares in Q1 2026, an estimated $408K.
AbbVie made up 0.17% of Cresset Asset Management's portfolio in Q1 2026, its #90 holding.
Cresset Asset Management first reported a position in AbbVie in Q4 2018 and has held it in 30 quarters since.
Cresset Asset Management's AbbVie position peaked at $67.7M in Q3 2024.
4,087 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Cresset Asset Management's 13F filing for Q1 2026, filed 15 May 2026.